DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Trident Lifeline Ltd (TLL) share price today?

Trident Lifeline Ltd (TLL) is trading at ₹260.9 on the BSE, up 0.00% on the day. Source: DocStoX.

What is the PE ratio of Trident Lifeline Ltd?

Trident Lifeline Ltd has a price-to-earnings (PE) ratio of 25.5 in the Healthcare sector.

What is the market capitalisation of Trident Lifeline Ltd?

Trident Lifeline Ltd has a market capitalisation of approximately ₹311 crore.

Trident Lifeline Ltd

TLL·BSE·Healthcare

₹260.90▲ +0.00 (+0.00%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Day₹260.05

₹263.65

52W₹230

₹32832%

Open

₹262.00

High

₹263.65

Low

₹260.05

Prev Close

₹260.90

Volume

31.2K

VWAP

₹260.87

Snapshot

Key fundamentals

Market Cap

₹311 Cr

P/E Ratio

25.53Fair

P/B Ratio

3.10

EPS

₹10.22

Book Value

₹84.14

ROE

15.07%Strong

ROCE

18.00%Decent

Dividend Yield

0.00%

Debt / Equity

0.73Moderate

Face Value

₹10.00

52W High

₹328.00

52W Low

₹229.95

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹97

▼ 63.0%downside

Trading at ₹261 — 63% above our estimate

BearFair valueBull

₹82₹97₹111

/100

Business quality — Solid

Growth 50Profitability 52Efficiency 50Valuation 62

Plain English

Our view

A steady, established business
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

15% ROE fading to 13% over ~10 yrs, on ₹84 book

₹94

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹106

Analyst target

No analyst coverage

—

Blended fair value₹97

What the numbers say

Investment thesis

Bull case

Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

25.5Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

15.1%Strong

Above 15% is considered healthy for Indian equities

ROCE

18.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.73Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹311 Cr

P/B

3.10

EPS

₹10.22

Div Yield

—

What changed

Recent changes

Foreign investors-2.0% stake last quarter
Promoters-0.26% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 25.5×

Growth

Strong

+59% rev CAGR

Profitability

Healthy

15.1% ROE

Financial health

Comfortable

D/E 0.73

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹81.39L Cr

Trades52

VWAP₹260.87

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+59.2%

—

10Y

—

Profit

+47.4%

—

10Y

—

EPS

+4.3%

—

10Y

—

Profile

Pros

Company is expected to give good quarter

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company might be capitalizing the interest cost
Company has high debtors of 208 days.
Promoter holding has decreased over last 3 years: -7.45%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters trimmed their stake by 0.26 pts; foreign investors sold 1.99 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

63%

Promoter

Promoters

62.6%-0.26

Public

20.6%+1.91

FII / FPI

5.3%-1.99

DII

0.3%-0.01

Others

11.3%

Total shareholders

709+102 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter62.59%

FII5.25%

DII0.26%

Public20.58%

Others11.32%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals products[1]